PowerPoint Presentation 38 31 36 25 29 23 18 20 22 10 9 13 4 5 2 5 6 3 0 20 40 60 80 100 120 ≤3 palms n = 2,497 4-10 palms n = 612 >10 palms n = 91 Pa tie nt s (% ) Topical + oral + biologic Oral + biologic Biologic ± topical Oral ± topical Topical only No medication UPLIFT More than half of UPLIFT patients with limited BSA (≤3 palms) perceived their PsO as moderate or severe Mark Lebwohl1; Richard G. Langley2; Carle Paul3; Lluis Puig4; Kristian Reich5; Peter van der Kerkhof6; Lihua Tang7; Sven Richter7; Benoit Guerette7; Paolo Gisondi8 1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Canada; 3Paul Sabatier University, Toulouse, France; 4Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; 5Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Department of Dermatology, Radboud University Medical Center, Nijmegan, Netherlands; 7Amgen Inc., Thousand Oaks, CA, USA; 8University Hospital of Verona, Verona, Italy • UPLIFT: Quantitative online survey from March 2, 2020, to June 3, 2020 – 4,729 participants (473 dermatologists, 450 rheumatologists, 3,806 patients) • MAPP: Telephone survey from June 2012 to August 20121,2,6 – 4,207 participants (391 dermatologists, 390 rheumatologists, 3,426 patients)1,2 • The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey provided valuable data on quality of life and unmet needs in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA)1,2 • Since the 2012 MAPP survey, PsO treatment options have increased1,3-5 • The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey was designed to better understand how perspectives on treatment-related outcomes have evolved since the MAPP survey, particularly for patients with mild to moderate disease. We present patient-reported data from UPLIFT and MAPP • More than half of patients in the UPLIFT survey perceived their current PsO symptoms as moderate or severe despite limited skin involvement. Additionally, many patients were not receiving any medication, suggesting that there remains significant unmet need Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey • More than half of patients with limited skin involvement reported their current disease as moderate or severe, had PsO involvement in special areas, and were receiving topicals or no treatment, suggesting a persistent unmet need in this patient population • In MAPP vs. UPLIFT, the proportion of patients describing their disease as moderate to severe on systematic treatment remained relatively low despite the higher number of available treatment options • Further research is needed to better understand why a significant proportion of patients with limited skin involvement and PsO in special areas perceive their current disease as moderate or severe but do not receive systemic treatment ML: Mount Sinai – employment; AbbVie, Amgen Inc., Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB – research funds; Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica – consultant. RGL: AbbVie, Amgen Inc., Boehringer Ingelheim, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, and UCB – principal investigator, scientific advisory board, or speaker. CP: No conflicts to disclose. LP: AbbVie, Amgen Inc., Boehringer Ingelheim, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB – fees; AbbVie, Almirall, Amgen Inc., Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, LEO Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB – honoraria and consultant fees; Celgene, Janssen, Lilly, MSD, Novartis, and Pfizer – company-sponsored speakers bureaus. KR: AbbVie, Affibody, Almirall, Amgen Inc., Avillion, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Covagen, Dermira, Forward Pharma, Fresenius Medical Care, Galapagos, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Miltenyi Biotec, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Sun Pharma, Takeda, UCB, Valeant, and Xenoport – paid speaker and/or participated in clinical trials. PvdK: AbbVie, Almirall, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly, Janssen, LEO Pharma, and Novartis – consultant and/or lecturer. LT, SR, & BG: Amgen Inc. – employment. PG: AbbVie, Amgen Inc., Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB – consultant and grant/research support. Funding Statement: This survey was funded by Amgen Inc. Writing support was funded by Amgen and provided by Amy Shaberman, PhD, of Peloton Advantage, LLC, an OPEN Health company. 1. Lebwohl MG, et al. J Am Acad Dermatol. 2014;70:871-881. 2. van de Kerkhof PC, et al. J Eur Acad Dermatol Venereol. 2015;29:2002-2010. 3. Otezla [package insert]. Thousand Oaks, CA: Amgen, Inc; 2020. 4. Ilumya [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2018. 5. Tremfya [package insert]. Horsham, PA: Janssen Biotech, Inc; 2017. 6. Lebwohl MG, et al. Am J Clin Dermatol. 2016;17:87-97. © 2021 Amgen Inc.Presented at: the 2021 Winter Clinical Dermatology Conference–Hawaii® UPLIFT N = 3,806 MAPP N = 3,426 Age, years, mean 45.1 54.8 Female, n (%) 1,892 (49.7) 2,026 (59.1) Comorbidities, n (%) Arthritis* 1,157 (30.4) 1,179 (34.4) Cancer 693 (18.2) 189 (5.5) Depression 1,257 (33.0) 626 (18.3) Diabetes 903 (23.7) 489 (14.3) Heart disease 520 (13.7) 345 (10.1) Hypertension 1,342 (35.3) 1,121 (32.7) Inflammatory bowel disease† 512 (13.5) 129 (3.8) Liver disease 419 (11.0) 71 (2.1) N represents the total sample. The number of patients with data available may vary. *Osteoarthritis or rheumatoid arthritis in UPLIFT and any arthritis in MAPP. †Crohn’s disease and ulcerative colitis. Results Patients in UPLIFT had higher rates of certain comorbidities but lower mean age vs. patients in MAPP • Both studies included adult patients (≥18 years of age) who reported that they had been diagnosed with PsO and/or PsA by a healthcare practitioner Conclusion Synopsis Methods Disclosures & Funding Statement In UPLIFT, 60% of PsO patients with limited BSA and involvement in ≥1 special area reported their current disease as moderate or severe Of these, 51% were receiving topicals or no treatment Body Surface Area In both surveys, high proportions of patients reported that they were not currently receiving treatment • In UPLIFT, 58% of patients with limited BSA rated their current PsO symptoms as moderate or severe • Many had PsO involvement in special areas (scalp, face, palms and/or soles, nails, genitals) and were not receiving treatment COUNTRIES United States Canada United Kingdom France Germany Italy Spain Japan UPLIFT patients MAPP1 patients N = 1,005 400 400 415 406 400 400 1,006 403 400 404 403 401 398 391N = Results Face: 28% Scalp: 54% Palms: 17% Nails: 17% Genitals: 12% Soles†: 13% UPLIFT n = 3,606 MAPP n = 2,416 Face: 15% Scalp: 48% Palms: 12% Nails: 11% Genitals: 7% Soles†: 11% *Among patients with PsO and presence of skin symptoms. †Soles of feet in UPLIFT; soles in MAPP. Note: A patient may have more than one special area. In both UPLIFT and MAPP: • Most patients had PsO • Similar proportions of patients reported having limited skin involvement (body surface area [BSA] ≤3 palms) 67% 5% 28% PsO only PsA only PsO + PsA 79% 7% 14% PsO only PsA only PsO + PsA UPLIFT N = 3,806 MAPP N = 3,426 Diagnosis Self-reported PsO Severity 0 20 40 60 80 100 UPLIFT n = 3,200 MAPP n = 2,549 Pa tie nt s, % BSA >10 palms BSA 4-10 palms BSA ≤3 palms 3 19 6 15 PsO in special areas was commonly reported in both surveys.* In UPLIFT, >50% of patients had scalp involvement 41 32 37 53 55 52 4 8 5 2 4 5 1 1 1 0 20 40 60 80 100 120 ≤3 palms n = 2,122 4-10 palms n = 393 >10 palms n = 166 Pa tie nt s (% ) Oral + biologic Biologic ± topical Oral ± topical Topical only No medication MAPP Body Surface Area 78 79 Objective • The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey was designed to better understand how perspectives on treatment-related outcomes have evolved since the MAPP survey, particularly for patients with mild to moderate disease. We present patient-reported data from UPLIFT and MAPP Slide Number 1